Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
The catastrophic failure of Pfizer's torcetrapib looked like it might doom an entire class of cholesterol modulators, but next month Merck will move its anacetrapib into one of the largest cardiovascular trials ever. Asher Mullard investigates how drug developers have reignited hope for the CETP inhibitors.